inVentiv Health, a Burlington, Mass.-based professional services organization, closed a private equity investment with Advent International.
Advent joined Thomas H. Lee Partners, L.P. as an equal equity owner of inVentiv Health. Its equity investment valued the company at $3.8 billion on a cash-free, debt-free basis.
The company will use the proceeds to accelerate the development and delivery of therapies for its global biopharmaceutical client base.
Led by Michael Bell, Chairman and Chief Executive Officer, InVentiv Health provides biopharmaceutical industry players with comprehensive and integrated clinical and commercial outsourcing services to accelerate the delivery of therapies to market. The company has approximately 15,000 employees supporting clients, including all 20 of the largest global biopharmaceutical companies, in 90 countries.